Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects

Rastogi, Meenal; Gupta, Sudeep; Sachan, Manisha

doi:10.1590/1678-4324-2016160070

Cited by 24 publications

(22 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the ROMA algorithm yielded 93% sensitivity at 75% specificity with a negative predictive value of 93-94%. ROMA was compared to the RMI and was found superior with 76% sensitivity obtained at 75% specificity in premenopausal patients [21]. ROMA achieved 94% sensitivity and the RMI 85% at 75% specificity.…”

Section: Multivariate Index/biomarker Based Algorithmmentioning

confidence: 94%

“…Using data from this pilot trial,a risk of malignancy algorithm (ROMA) was developed by Skates and Moore, incorporating CA 125, HE4 and menopausal status, imaging data were not included [21] premenopausal and for postmenopausal women with pelvic masses had separate logistical formulas, assigning them to high and low risk groups. Overall, the ROMA algorithm yielded 93% sensitivity at 75% specificity with a negative predictive value of 93-94%.…”

Section: Multivariate Index/biomarker Based Algorithmmentioning

confidence: 99%

See 1 more Smart Citation

Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

Kumari

2018

Ind J Clin Biochem

View full text Add to dashboard Cite

Epithelial ovarian cancer accounts for more than 90% of ovarian tumours and continues as a leading cause of death from gynaecological malignancies. It is often difficult to differentiate a benign ovarian mass from malignant ones. Invasive histopathological biopsy is used as the gold standard diagnostic tool to diagnose cancer in patients with ovarian mass. A wide spectrum of Biomarkers were tried in various studies to develop a non invasive diagnostic tool, out of which HE4 and CA 125 remain the only clinically useful biomarker. Consequently various Biomarker based algorithms i.e. Risk of Malignancy Index, risk of ovarian cancer algorithm, OVA1, risk of malignancy algorithm were generated that have been developed to assess the risk of a mass being malignant. These algorithms help in timely triage of patients. Recently in 2016 FDA cleared Ova1 test (OVERA) with CA 125-II, HE4, apolipoprotein A-1, FSH, and transferring (Sensitivity 91% and Specificity 69%) as a referral or Triage test in patients presenting with ovarian mass. Combination of protein and circulating Micro RNA analysis in blood, could provide a comprehensive screening and diagnostic panel, in management of patients presenting with ovarian mass in one clinical setting.

show abstract

Section: Multivariate Index/biomarker Based Algorithmmentioning

confidence: 94%

Section: Multivariate Index/biomarker Based Algorithmmentioning

confidence: 99%

Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

Kumari

2018

Ind J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is the fifth death-causing cancer in the United States, and every year around 22,000 cases have been recorded [26]. It is one of the gynecologic cancers, affecting all parts of the reproductive system including the uterus, ovary, and cervix.…”

Section: Ovarian Cancermentioning

confidence: 99%

Recent Advances in Identifying Biomarkers and High-Affinity Aptamers for Gynecologic Cancers Diagnosis and Therapy

Lakshmipriya

Gopinath

2019

Journal of Analytical Methods in Chemistry

View full text Add to dashboard Cite

Cancer is the uncontrollable abnormal division of cell growth, caused due to the varied reasons. Cancer can be expressed in any part of the body, and it is one of the death-causing diseases. Human reproductive organs are commonly damaged by cancer. In particular, the women reproductive system is affected by various cancers including ovarian, cervical, endometrial, vaginal, fallopian tube, and vulvar cancers. Identifying these cancers at earlier stages prevents the damage to the organs. Aptamer is the potential probe that can identify these cancers. Aptamer is an artificial antibody selected from the randomized library of molecules and has a high binding affinity to the target biomarker. Targeting cancers in the reproductive organs using aptamers showed an excellent efficiency of detection compared to other probes. Different aptamers have been generated against the gynaecological cancer biomarkers, which include HE4, CA125, VEGF, OCCA (for ovarian cancer), EGFR, FGFR1, K-ras (for endometrial cancer), HPV E-16, HPV E-7, HPV E-6, tyrosine, and kinase (for cervical cancer), which help to identify the cancers in woman reproductive organs. In this overview, the biomarkers for gynecologic cancers and the relevant diagnosing systems generated using the specific aptamers are discussed. Furthermore, the therapeutic applications of aptamer with gynaecological cancers are narrated.

show abstract

“…Traditionally, single-biomarker time-series have been employed for the screening of ovarian cancer patients, particularly CA125 data. Recently, a few studies [6] , [12] , [32] , [33] have suggested that different biomarkers can be combined into multidimensional time-series and can lead to more accurate diagnosis. We explore this approach in the sequel.…”

Section: Datamentioning

confidence: 99%